| | PD-L1 antibody | Cutoff for positivity of PD-L1 expression in tumor cell membrane | Percentage of tumor samples expressing PD-L1 | Study reference |
| | 28-8 | 5% | 49% | Grosso et al., JCO, 2013 [37] | | R&D B7-H1 | NR | 52% | Gatalica et al., CEBP, 2014 [38] | | MIH1 | >10% | 50% | Konishi et al., CCR, 2004 [39] | | 5H1 | >1% versus >5% versus high score | 21% (only CEC) | Marti et al., CCR, 2014 [30] | | SP142 | 5% | 60% | | | NR | 1% | 50% | Sun et al., JCO, 2014 [40] | | 22C3 | ≥50% | 25% | Garon et al., NEJM, 2015 [27] | | 28-8 | ≥1%, ≥5%, ≥10% | 53%, 36%, 25% (only CEC) | Brahmer et al., NEJM, 2015 [33] | | SP142 | ≥1%, ≥5%, ≥10% | 68%, 37%, 16% | | | SP142 | ≥1%, ≥5%, ≥10% | 56%, 28%, 13% | Herbst et al., Nature, 2014 [41] |
|
|
